Immunotherapy Stocks List
Symbol | Grade | Name | % Change | |
---|---|---|---|---|
FBIOP | B | Fortress Biotech, Inc. - 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock | 0.13 | |
ARGX | B | argenx SE | -0.05 | |
GLSI | B | Greenwich LifeSciences, Inc. | -5.01 | |
MRKR | C | Marker Therapeutics, Inc. | -0.95 | |
IMTX | C | Immatics N.V. | -1.66 | |
ADAG | C | Adagene Inc. | -3.01 | |
ALBT | C | Avalon GloboCare Corp. | 14.71 | |
URGN | C | UroGen Pharma Ltd. | -0.86 | |
NXTC | C | NextCure, Inc. | 4.67 | |
REPL | D | Replimune Group, Inc. | -3.35 |
Related Industries: Biotechnology Broadcasting - TV Diagnostics & Research Medical Care Medical Devices Other
Symbol | Grade | Name | Weight | |
---|---|---|---|---|
SBIO | D | ALPS Medical Breakthroughs ETF | 1.87 | |
BBC | D | Virtus LifeSci Biotech Clinical Trials ETF | 1.71 | |
XBI | B | SPDR S&P Biotech ETF | 0.63 | |
BTEC | C | Principal Healthcare Innovators Index ETF | 0.55 | |
FYC | C | First Trust Small Cap Growth AlphaDEX Fund | 0.45 |
Compare ETFs
Date | Stock | Title |
---|---|---|
Jun 28 | ARGX | Argenx: Strong Setup For Outperformance In 2025 |
Jun 27 | URGN | UroGen Pharma Stock Earns 91 RS Rating |
- Immunotherapy
Immunotherapy is the treatment of disease by activating or suppressing the immune system. Immunotherapies designed to elicit or amplify an immune response are classified as activation immunotherapies, while immunotherapies that reduce or suppress are classified as suppression immunotherapies.
In recent years, immunotherapy has become of great interest to researchers, clinicians and pharmaceutical companies, particularly in its promise to treat various forms of cancer.Immunomodulatory regimens often have fewer side effects than existing drugs, including less potential for creating resistance when treating microbial disease.Cell-based immunotherapies are effective for some cancers. Immune effector cells such as lymphocytes, macrophages, dendritic cells, natural killer cells (NK Cell), cytotoxic T lymphocytes (CTL), etc., work together to defend the body against cancer by targeting abnormal antigens expressed on the surface of tumor cells.
Therapies such as granulocyte colony-stimulating factor (G-CSF), interferons, imiquimod and cellular membrane fractions from bacteria are licensed for medical use. Others including IL-2, IL-7, IL-12, various chemokines, synthetic cytosine phosphate-guanosine (CpG) oligodeoxynucleotides and glucans are involved in clinical and preclinical studies.
Recent Comments
- TraderMike on Bollinger Band Squeeze
- TraderMike on Bollinger Band Squeeze
- OpenCat584 on Bollinger Band Squeeze
- Dr_Duru on Expansion Breakout
- TraderMike on New Scans: Strong, Oversold Stocks and Weak, Overbought Stocks
From the Blog
Featured Articles